HDFC Securities has an ‘add’ call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore for the quarter ending 31-12-2024, marking an 11.59% increase from the same quarter last year. The diagnostic sector’s de-rating and moderate earnings growth influenced the latest valuation estimates.